Alzhiemer's Cure in the Making? Biogen's Drug Shows Remarkable Results in Trial

An experimental drug from Biogen holds the promise of a cure for millions affected with Alzheimer's.

The drug, Aducanumab, was tested in 166 people at various stages of the disease and was found to have the most pronounced effect in those with early or mild forms of the condition. Brain scans before and treatment with the drug showed a significant reduction in amyloid plaque and reduced impairment of patients compared to the test group given a placebo. Plaque formation or amyloidosis plays a major role in neurological disorders.

Researchers found that improvement in signs of cognitive impairment and plaque reduction were more pronounced as the dose of the drug was increased.

The drug is being hailed as the first to demonstrate such success during experimentation. Its success is set to motivate researchers to conduct a larger phase III clinical trials, where researchers expect similar success. At highest doses, the drug caused a 70 percent reduction in cognitive decline.

The New York Times reported that at its highest doses, the drug caused brain swelling which forced some participants to drop out. It was also reported that the drug was more effective than other drugs, including those from Eli Lilly and Roche, in trial phase.

Nearly 36 million people worldwide are affected by Alzheimer's, which could double in the next 15 years placing an enormous health and economic burden. There currently is no cure for the disease.